AU2001244192A1 - Use of pyrido(3,2-E)-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction - Google Patents

Use of pyrido(3,2-E)-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction

Info

Publication number
AU2001244192A1
AU2001244192A1 AU2001244192A AU4419201A AU2001244192A1 AU 2001244192 A1 AU2001244192 A1 AU 2001244192A1 AU 2001244192 A AU2001244192 A AU 2001244192A AU 4419201 A AU4419201 A AU 4419201A AU 2001244192 A1 AU2001244192 A1 AU 2001244192A1
Authority
AU
Australia
Prior art keywords
pyrazinones
pyrido
phosphodiesterase
inhibitors
erectile dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001244192A
Inventor
Ute Egerland
Norbert Hofgen
Thomas Kronbach
Degenhard Marx
Stefan Szelenyi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elbion GmbH
Original Assignee
Arzneimittelwerk Dresden GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arzneimittelwerk Dresden GmbH filed Critical Arzneimittelwerk Dresden GmbH
Publication of AU2001244192A1 publication Critical patent/AU2001244192A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2001244192A 2000-03-14 2001-03-06 Use of pyrido(3,2-E)-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction Abandoned AU2001244192A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10012373A DE10012373A1 (en) 2000-03-14 2000-03-14 Treating erectile dysfunction using new or known imidazo(1,5-a)pyrido(3,2-e)pyrazinone derivatives, as cGMP-selective phosphodiesterase V inhibitors free of cardiovascular side-effects
DE10012373 2000-03-14
PCT/EP2001/002485 WO2001068097A1 (en) 2000-03-14 2001-03-06 Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction

Publications (1)

Publication Number Publication Date
AU2001244192A1 true AU2001244192A1 (en) 2001-09-24

Family

ID=7634668

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001244192A Abandoned AU2001244192A1 (en) 2000-03-14 2001-03-06 Use of pyrido(3,2-E)-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction

Country Status (14)

Country Link
EP (1) EP1267877A1 (en)
JP (1) JP2003528056A (en)
AR (1) AR028250A1 (en)
AU (1) AU2001244192A1 (en)
BG (1) BG107077A (en)
BR (1) BR0109163A (en)
CZ (1) CZ20023078A3 (en)
DE (1) DE10012373A1 (en)
HU (1) HUP0300551A2 (en)
IL (1) IL151646A0 (en)
NO (1) NO20024364L (en)
RU (1) RU2002127413A (en)
SK (1) SK13232002A3 (en)
WO (1) WO2001068097A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (en) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
EA019085B1 (en) 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
JP2011505366A (en) 2007-11-30 2011-02-24 ワイス・エルエルシー Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphoesterase 10
WO2010025890A1 (en) 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
AU2009319387B2 (en) 2008-11-28 2012-05-10 Addex Pharma S.A. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5634506B2 (en) 2009-05-12 2014-12-03 ジャンセン ファーマシューティカルズ， インコーポレイテッド 1,2,3-Triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5852666B2 (en) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor
ES2552455T3 (en) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JP5852665B2 (en) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor
JP6240180B2 (en) 2012-06-18 2017-11-29 ダート・ニューロサイエンス・（ケイマン）・リミテッド Substituted thiophene- and furan-fused azolopyrimidin-5- (6H) -one compounds
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
LT3096790T (en) 2014-01-21 2019-10-10 Janssen Pharmaceutica, N.V. Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
JP6420400B2 (en) * 2017-04-12 2018-11-07 ダート・ニューロサイエンス・（ケイマン）・リミテッド Substituted pyridine azolopyrimidin-5- (6H) -one compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
AU3767793A (en) * 1992-04-03 1993-11-08 Yamanouchi Pharmaceutical Co., Ltd. Fused quinoxalinone derivative and pharmaceutical composition containing the same
DE4228095A1 (en) * 1992-08-24 1994-03-03 Asta Medica Ag New 4,5-dihydro-4-oxopyrrolo [1,2-a] quinoxalines and corresponding aza analogues and processes for their preparation
DE4338948A1 (en) * 1993-11-15 1995-05-18 Carlen Judith Treating erectile dysfunction without causing side-effects
DE19510965A1 (en) * 1995-03-24 1996-09-26 Asta Medica Ag New pyrido / 3,2-e / pyrazinone with anti-asthmatic activity and process for their preparation
DE19728301A1 (en) * 1997-07-03 1999-01-07 Dresden Arzneimittel Use of inhibitors of phosphodiesterase 4 for the treatment of allergic rhinitis

Also Published As

Publication number Publication date
AR028250A1 (en) 2003-04-30
NO20024364D0 (en) 2002-09-12
JP2003528056A (en) 2003-09-24
CZ20023078A3 (en) 2003-03-12
WO2001068097A1 (en) 2001-09-20
SK13232002A3 (en) 2003-05-02
BG107077A (en) 2003-05-30
BR0109163A (en) 2002-11-26
DE10012373A1 (en) 2001-09-20
IL151646A0 (en) 2003-04-10
EP1267877A1 (en) 2003-01-02
HUP0300551A2 (en) 2003-07-28
RU2002127413A (en) 2004-02-27
NO20024364L (en) 2002-09-27

Similar Documents

Publication Publication Date Title
AU2001244192A1 (en) Use of pyrido(3,2-E)-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction
IL138907A0 (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
HK1051368A1 (en) Beta-carboline derivatives useful as inhibitors of phosphodiesterase
HK1084384A1 (en) Pyrazolo [3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
EP1027054A4 (en) Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO2002102313A3 (en) Pyrimidine inhibitors of phosphodiesterase (pde) 7
HK1069970A1 (en) Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
PL363150A1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
ZA200204510B (en) Imidazopyridine derivatives used as phosphodiesterase VII inhibitors.
AU4314199A (en) Compounds, compositions and methods for treating erectile dysfunction
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
AU2002221753A1 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
IL155386A0 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
HUP0200912A2 (en) Compositions comprising phosphodiesterase inhibitors for the treatment of sexual disfunction
SI1534707T1 (en) Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
HK1047434A1 (en) Thienopyrimidines as phosphodiesterase inhibitors.
ZA200007019B (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence.
EP1090644A3 (en) Combination effective for the treatment of impotence comprising a potassium-channel-opener and a cGMP elevator
HUP0300477A3 (en) Daily treatment for erectile dysfunction using a composition containing pde5 inhibitors
NZ530587A (en) Diazacycloalkanes as oxytocin agonists
AU2001237379A1 (en) Use of benzothieno-2,3-D-pyrimidines with PDE V inhibitory effect for the treatment of erectile dysfunction
AU2000275972A1 (en) Pde iii inhibitors for treating sexual dysfunction
WO2001044235A3 (en) Agents and methods for the treatment of proliferative diseases
EP1395593A4 (en) Novel pyrazolopyrimidinethione derivatives. preparation methods thereof and their use as therapeutics for erectile dysfunction